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ABSTRACT  
 
Duchenne Muscular Dystrophy (DMD) is the most common and severe form of muscular 
dystrophy in humans. The goal of myogenic stem cell transplant therapy for DMD is to increase 
dystrophin expression in existing muscle fibers and provide a source of stem cells for future 
muscle generation. Although syngeneic myogenic stem cell transplants have been successful in 
mice, allogeneic transplants of myogenic stem cells were ineffective in several human trials. To 
determine whether allogeneic muscle progenitor cells can be successfully transplanted in an 
immune tolerant recipient, we induced immune tolerance in two DMD affected (xmd) dogs 
through hematopoietic cell transplantation (HCT). Injection of freshly isolated muscle-derived 
cells from the HCT donor into either fully or partially chimeric xmd recipients restored 
dystrophin expression up to 6.72% of wild-type levels, reduced the number of centrally located 
nuclei, and improved muscle structure. Dystrophin expression was maintained for at least 24 
weeks. Taken together, these data indicate that immune tolerance to donor myoblasts provides an 
important platform from which to further improve myoblast transplantation, with the goal of 
restoring dystrophin expression to patients with DMD. 
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INTRODUCTION 
 Duchenne Muscular Dystrophy (DMD) is the most common and severe form of muscular 
dystrophy in humans, affecting 1 in 3500 live births [1,2]. It is an X-linked recessive disorder, 
caused by mutations in the gene for dystrophin, the largest gene identified in the human genome. 
Mutations are present at birth, yet symptoms do not manifest themselves until 3-5 years of age. 
Progressive muscle weakness and wasting forces affected individuals to become wheelchair-
bound by 12 years of age, and to succumb to the disease in the third decade of life as a result of 
respiratory and/or cardiac failure.  
Transplantation of myogenic stem cells possesses great potential for long-term repair of 
dystrophic muscle. Indeed, intramuscular injection of adult satellite cell-derived myoblasts from 
a normal syngeneic donor into mdx mice results in the formation of dystrophin-positive muscle 
fibers [3-6]. However, small-scale human clinical trials reveal that intramuscular injection of 
donor myoblasts results in transient expression of dystrophin in a small number of recipient 
muscle fibers [7-12]. In the absence of immunosuppression, injection of donor myoblasts triggers 
cellular immune responses that destroy newly formed donor myotubes [13].  
Immunosuppressive drugs, such as cyclosporine and FK506, inhibit calcineurin activity 
and prevent graft rejection. Yet, patients treated with cyclosporine do not display an increased 
number of dystrophin-positive myofibers relative to patients receiving placebo [10]. It has been 
established that cyclosporine alone is not potent enough to prevent graft rejection; additionally, 
cyclosporine may negatively affect myoblast engraftment, as calcineurin activity is essential for 
myogenic differentiation in vitro and in vivo [14,15]. More importantly, chronic systemic 
immunosuppression is associated with serious side effects and considerable risk. Regarded 
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together, these observations indicate that myogenic stem cell transplant therapy requires an 
alternative to traditional immunosuppression. 
 Nonmyeloablative hematopoietic cell transplantation (HCT) results in mixed chimerism, 
defined as the coexistence of donor and recipient hematopoietic cells [16]. In the clinic, 
nonmyeloablative transplantation is an outpatient procedure that has been well-tolerated in more 
than 1200 patients with malignant and non-malignant blood disorders [17]. Mixed chimerism in 
both rodents and large animals has successfully induced tolerance to donor-derived kidney, liver, 
small bowel, heart, lung, and pancreatic islet cells, without the need for immunosuppression [18-
23]. Specifically, donor kidneys transplanted into mixed chimeric canine recipients were fully 
functional and remained intact for at least 5 years, even when only 10% of lymphocytes within 
the recipient were of donor origin. 
 Therefore, we sought to determine if HCT could be used to establish an immune tolerant, 
random-bred, large animal model of DMD for pre-clinical myogenic stem cell transplantation 
studies. The canine model of DMD (cxmd) is characterized by a point mutation in the consensus 
splice acceptor site in intron 6 of the dystrophin gene, introducing a stop codon within the 
modified reading frame, resulting in a near complete absence of dystrophin protein [24-26]. The 
dystrophic phenotype of the xmd canine faithfully recapitulates the human disease, making this 
an ideal model to investigate potential therapies. HCT alone is unable to restore dystrophin 
expression to xmd canines [27]. Therefore, we specifically asked if myeloablative and non-
myeloablative HCT in xmd canines would permit donor-derived myogenic stem cells to stably 
engraft and restore dystrophin expression.  
Molecular Therapy   Manus \ Parker \ Parker_Hct-DMD.doc  4/23/2008 1:51 PM  5 
RESULTS 
 
HCT and myoblast transplantation protocol 
Bone marrow and G-CSF mobilized peripheral blood mononuclear cells (PBMCs) were 
harvested from two normal donors and transplanted into two irradiated DLA-identical cxmd 
recipients (Figure 1a, Materials and Methods). The hematopoietic cells of one cxmd recipient 
were all donor derived (Table 1; G289; full chimera), whereas the second recipient had a mix of 
donor and recipient hematopoietic cells (Table 1; G604; mixed chimera). Skeletal muscle-
derived mononuclear cells isolated from the same donors were processed for injection 
immediately after isolation or cultured for 14 days to specifically expand myogenic cells prior to 
injection (Figure 1b, Materials and Methods). G289 underwent the myeloablative HCT at 5.5 
months of age, followed by myoblast transplantation at 32 months of age. G604 underwent the 
nonmyeloablative HCT at 7 months of age, and myoblast transplantation at 18 months of age. 
     
Injection of donor muscle-derived cells restored dystrophin expression in chimeric xmd 
canines 
Enzymatic digestion of a skeletal muscle biopsy from the HCT donor released a mixed 
population of mononuclear cells that included, but was not limited to, satellite cells and 
fibroblasts. Freshly isolated muscle-derived cells were injected intramuscularly at several sites in 
the biceps femoris muscle of chimeric recipients. Cryosections from biopsies taken between four 
and twenty-four weeks post-injection were analyzed for dystrophin expression. It was expected 
that if cells injected into the skeletal muscle of the xmd chimeric dog were differentiation and 
fusion competent, then dystrophin expression would be restored.  
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Indeed, intramuscular injection of 1x106 fresh donor muscle derived cells into the fully 
chimeric cxmd recipient, G289, restored dystrophin expression to muscle fibers in muscle 
biopsies taken at five and ten weeks after injection (Figure 2a). Dystrophin expression was 
observed throughout the biopsy, extending approximately 0.5 cm from the site of injection (data 
not shown). Similarly, injection of 4.5x106 freshly isolated donor muscle-derived cells directly 
into the muscle of the mixed chimeric xmd canine, G604, resulted in clusters of dystrophin 
expressing fibers, grouped near the sites of injection in biopsies at 4, 8, and 24 weeks after 
injection (Figure 2b). Expression of dystrophin appeared to be maintained over at least 1000 μm 
of fiber length, as assessed by examination of serial sections (data not shown).  
 
Quantitation of donor contribution in injected cxmd recipient muscle 
The amount of donor derived wild-type dystrophin mRNA was assessed by real-time RT-PCR 
using a probe that specifically recognizes the wild-type dystrophin splice junction and not the 
abnormal spliced form in cxmd muscle. The level of dystrophin mRNA observed in wild-type 
donor muscle was arbitrarily set to 100, and resulted in a relative level of dystrophin mRNA of 
0.00035% in the fully chimeric cxmd recipient (G289) before muscle-derived cell 
transplantation. The level of dystrophin in G289 increased significantly to 6.48% (p =0.0007) ten 
weeks after injection of freshly isolated cells.  
The relative level of skeletal muscle dystrophin mRNA in G604 was 0.0019% before 
muscle-derived cell transplantation (Table 2). This increased to 1.29% (p =0.003) 4 weeks after 
injection of fresh cells, and remained constant at 24 weeks after injection at 1.32% (p=0.01). 
Therefore, in both G289 and G604, the values for dystrophin expression were significantly 
higher after muscle-derived cell transplantation. Because mononuclear satellite cells and muscle 
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stem cells do not express dystrophin, this indicates that the donor muscle-derived cells 
differentiated into dystrophin expressing myotubes. 
Genomic DNA (gDNA) isolated from groups of cryosections serially cut from biopsies of 
injected muscle and analyzed by VNTR-PCR confirmed the persistence of significant amounts of 
donor-derived cell DNA at the latest time points of analysis. The fully chimeric xmd dog, G289, 
displayed an average of 13.9% donor gDNA pre-injection, representing donor blood cell nuclei 
present as the result of hematopoietic cell transplantation (Table 3). Ten weeks after injection of 
freshly isolated cells, an average of 20.2% of gDNA was donor-derived (p=0.0017), and the 
highest value of donor contribution to gDNA was 23.1%. The mixed chimeric xmd dog, G604, 
displayed an average of 5.0% donor gDNA before injection of muscle-derived cells. Twenty-four 
weeks after injection of freshly isolated cells, an average of 9.3% was donor-derived (p =0.007), 
with the highest value of donor contribution to gDNA was 12.3%.  
 
Injection of donor muscle-derived cells did not elicit an immune response in HCT 
Transplanted Recipients  
To determine if injection of donor muscle-derived cells induced an immune response and 
infiltration of host immune cells in the recipient, cryosections were immunostained using 
antibodies directed against CD45, a hematopoietic cell marker; CD3, a T-cell specific marker; 
and CD14, a monocyte/macrophage-specific marker. Minimal hematopoietic cell infiltration was 
observed in donor and dystrophic recipient skeletal muscle pre-transplantation, as evidenced by 
occasional CD45 expressing cells (Figure 2c – donor, recipient pre-injection). There was an 
absence of CD3-positive T cells (data not shown), yet CD14-positive macrophages were clearly 
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observed in small patches within the recipient DMD-affected muscle pre-injection (Figure 2d – 
recipient pre-injection), confirming the mild inflammatory process associated with DMD.  
 At 10 weeks after cell transplantation, a persistent minimal lymphocytic infiltration was 
observed (Figure 2c – CD45). Careful examination of immunostained cryosections uncovered no 
CD3-positive cells (data not shown); however, a small region of CD14-positive cells was 
detected, indicative of monocytes/macrophages, which normally infiltrate degenerating skeletal 
muscle (Figure 2d – recipient after injection). Therefore, injection of donor muscle-derived cells 
into cxmd muscle did not induce immune cell infiltration. 
 
Intramuscular injection of donor muscle-derived cells restored muscle structure and 
reduced regeneration in chimeric xmd canine 
For stem cell therapy to be effective and clinically relevant, function must be restored to skeletal 
muscle. However, the localized injections used in this study precluded testing for functional 
improvement. Therefore, we evaluated improvement in muscle structure and stability through 
histological examination. Hematoxylin and eosin staining of cryosections from the G289 
recipient muscle pre-transplantation revealed a striking loss of muscle structure, considerable 
variation in muscle fiber size, and increased fatty and connective tissue as compared to normal 
donor muscle (Figure 3a – donor, recipient pre-injection). Injection of freshly isolated muscle-
derived cells markedly improved muscle structure at 10 weeks after transplantation and resulted 
in less connective and fatty tissue infiltration and reduced size variation in fiber diameter when 
compared to the pre-cell injection biopsy (Figure 3a).  
 Newly formed skeletal muscle fibers or fibers that have acquired differentiating myocytes 
as a result of regeneration are characterized by nuclei located in the center of the muscle fiber. In 
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donor wild-type muscle, less than 1% of muscle nuclei were centrally located. However, 
approximately 10% of muscle nuclei in the G289 DMD-affected recipient were centrally located, 
indicating that a portion of dystrophic muscle was regenerating (Figure 3b). Injection of fresh 
muscle-derived cells reduced the number of centrally located myonuclei in the G289 DMD-
affected recipient muscle to less than 5%, which was statistically significant as compared to the 
recipient before injection (p<0.01). Together, these findings suggested that engraftment of donor 
muscle-derived cells and restoration of dystrophin expression stabilized cxmd muscle, preventing 
repeated attempts to regenerate. 
 
Cultured donor muscle-derived cells restore dystrophin expression 
 Our data demonstrate that direct injection of freshly isolated donor-derived muscle cells 
engraft without immune rejection in chimeric recipients. However, many muscle stem cell 
transplant procedures require expansion of cells in culture, which might alter the immunogenic 
status of the donor cells. Therefore, to determine whether similar engraftment could be obtained 
by cells expanded in culture, donor muscle-derived cells were cultured before injection into 
biceps femoris muscle of the chimeric cxmd recipients. We used a standard serial pre-plating 
technique to enrich for myoblasts and analyzed cells from pre-plates 2 (PP2) and 6 (PP6) (Figure 
1b). In order to ensure that donor muscle-derived mononuclear cells were myogenic, adherent 
PP2 and PP6 cells were fixed in proliferation (Supplemental Figure 1a) and differentiation 
(Supplemental Figure 1b) conditions. Immunostaining with antibodies specific to desmin and 
Pax7, two markers of myoblasts in culture, established that more than 90% of proliferating 
cultured cells were myogenic. 
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 To assess differentiation potential in vitro, PP2 and PP6 cells were cultured until 
confluent, and fixed after an additional 72 hours. The PP2 population differentiated to form 
multinucleated myotubes that expressed myogenin and myosin heavy chain (MyHC), two 
markers of myogenic differentiation (Supplemental Figure 1b – PP2). The PP6 population also 
expressed myogenin and MyHC, yet remained primarily mononuclear (Supplemental Figure 1b – 
PP6). Mouse muscle-derived cells cultured in a comparable manner exhibited similar results 
[28,29]. 
Similar to direct injection of freshly isolated muscle-derived cells, injection of cultured 
PP6 cells did not induce immune cell infiltration in the injected muscle (data not shown). In 
addition, the injection of cultured PP6 cells restored dystrophin expression to skeletal muscle of 
chimeric cxmd recipients (Figure 4a and b). The level of dystrophin reached a maximum of 
1.45% of wild-type levels in the fully chimeric dog, G289, and 0.05% in the mixed chimeric dog, 
G604 (Table 4). Although these were significantly higher relative to the recipient levels before 
muscle cell transplantation (p =0.0026 and p =0.009, respectively), the maximum levels of wild-
type dystrophin was less than that reached after injection of freshly isolated cells (Table 2).  
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DISCUSSION 
Finding a clinically relevant means of restoring long-term expression of dystrophin to 
skeletal muscle has been a continuing challenge in the field of Duchenne muscular dystrophy 
research. Transplantation of normal myoblasts into human patients was unsuccessful, due to 
immune rejection of donor cells. While long-term immunosuppression might lengthen muscle 
cell survival, it is toxic to many organs, including kidneys, liver, muscle, bone, and the central 
nervous system, and leaves patients vulnerable to opportunistic infections. In this study, we 
demonstrated that HCT established immune tolerance in cxmd canines, permitting stable 
engraftment of donor muscle-derived cells in the absence of pharmacological 
immunosuppression. Importantly, donor muscle-derived cells restored dystrophin expression for 
at least 24 weeks following transplantation.  
Although dystrophin protein was detected extensively throughout cryosections from 
muscle biopsies obtained after cell injection, the level of dystrophin transcript was relatively low. 
Notably, it has been suggested in exon-skipping studies that in-frame dystrophin mRNA needs to 
achieve only 10% of total dystrophin levels to revert affected muscle to a mild Becker phenotype 
[30]. However, it is possible that the level of mRNA observed may not accurately reflect the 
level of protein present [31]. Although dystrophin protein is easily detected by antibody staining 
of muscle cryosections, dystrophin is estimated to represent less than 0.01% of cytoplasmic RNA 
present in adult skeletal muscle [32], suggesting that the muscle fiber may produce only limiting 
amounts of dystrophin transcript, yet translate the message efficiently into protein. As such, 
measuring the level of dystrophin transcript may not accurately represent the level of functional 
dystrophin protein. 
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 Recent studies of allogeneic transplantation of 107 cultured donor myoblasts into DMD 
patients using a “high density injection” protocol resulted in 3.5% to 26% of dystrophin-positive 
fibers within the injection site area at 4 weeks after transplantation [33], and in one patient some 
muscle regions had 34.5% positive fibers 18 months after transplantation [34]. This protocol 
relied on the use of FK506 to prevent immune rejection. In our study we demonstrate that 
injection of 10- to 20-fold fewer freshly isolated cells resulted in dystrophin expressing fibers 
that encompassed approximately 30-70% of fibers within the region of injection. Importantly, 
sustained engraftment did not depend on immunosuppression. This is a crucial distinction, as 
side effects of FK506 treatment include tremors, hypertension, renal dysfunction, 
hypomagnesemia, neurological toxicity, and long-term toxicity to liver and kidneys. 
Although only two dogs were included in our study, it is important to note that results 
from separate injection sites within the same dog consistently showed a similar pattern of 
dystrophin expression. Furthermore, dystrophin expression was clearly restored in the both 
chimeric dogs. Given that HCT induces tolerance to other organs, such as the kidney, lung, and 
small intestine, the small number of animals in this study nonetheless represent a definitive 
demonstration of allogeneic tolerance to donor myoblasts, and provides an important model from 
which to further improve dystrophin expression after myogenic cell transplantation.  
 Achieving greater dystrophin expression requires improving donor muscle-derived cell 
engraftment. Chimeric xmd canines provide a model in which to optimize donor muscle-derived 
cell isolation methods and test molecules that stimulate donor cell proliferation or reprogram 
recipient muscle to enhance fusion. More than 40 years of success in translating results from 
canines to humans in the clinic highlights that HCT is a clinically relevant platform from which 
to study and improve myoblast transplantation.  
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MATERIALS AND METHODS 
Hematopoietic cell transplantation. The Institutional Animal Care and Use Committee at the 
Fred Hutchinson Cancer Research Center, which is fully accredited by the Association for 
Assessment and Accreditation of Laboratory Animal Care, approved this study. Elevated 
enclosed runs were used for housing, and dogs were maintained in social groups wherever 
possible. All dogs were enrolled in a veterinary preventative medicine program that included 
routine anthelmintics and a standard immunization series against canine distemper, parvovirus, 
adenovirus type 2, parainfluenza virus, coronavirus, and rabies.  
Mixed breed xmd canines were maintained as a colony at the Fred Hutchinson Cancer 
Research Center, as previously described [27]. Littermates composed of healthy wild-type 
donors and xmd recipient dogs were matched by intrafamilial histocompatibility typing using two 
polymorphic satellite markers – one located in the class I region and one located in the class II 
region of the major histocompatibility complex [35,36]. Matching was confirmed in all cases by 
DRB1 gene sequencing [37].  
 The HCT protocol for xmd canines was described previously [27]. The day of HCT was 
designated as Day 0. Donor marrow cells were aspirated 30 days before transplant, under general 
anesthesia through needles inserted into the humeri and femora, and cryopreserved. 
Subcutaneous injections of recombinant canine granulocyte colony stimulating factor (rcG-CSF; 
5mg/kg b.i.d.; gift from Amgen, Thousand Oaks, CA) into the donor from day -5 to -1, was used 
to mobilize hematopoietic stem cells from the bone marrow to the peripheral blood. 
Leukaphereses for collection of G-CSF–“mobilized” peripheral blood mononuclear cells (G-
Molecular Therapy   Manus \ Parker \ Parker_Hct-DMD.doc  4/23/2008 1:51 PM  14 
PBMCs) were performed on Day 0 using a percutaneous central dual-lumen catheter [38] and a 
continuous flow blood separator (Cobe 2997; Cobe BCT, Lakewood, CO [39]). 
 On Day 0, each recipient received TBI at a single dose delivered at 7 cGy/min from a 
linear accelerator (Varian CLINAC 4, Palo Alto, CA) [40]. One recipient received 200 cGy, and 
the other received 920 cGy. Within 4 hours of TBI, thawed donor bone marrow cells and freshly 
isolated G-PBMCs were infused intravenously. Postgrafting immunosuppression consisted of 
oral cyclosporine (CSP), 10 mg/kg twice daily, from Day -2 to Day 35 [41]. All dogs were given 
standard supportive care that included subcutaneous fluids with electrolytes, systemic antibiotics.  
 
Chimerism and fluorescent VNTR-PCR. Hematopoietic chimerism was monitored weekly for 
the first 8 weeks, biweekly for the next 10 weeks, and monthly thereafter. Donor chimerism was 
considered stable 28 weeks post-HCT. Peripheral blood samples were separated into 
lymphocytes, granulocytes, and red blood cells by Ficoll-Hypaque gradient fractionation. 
Genomic DNA (gDNA) was isolated from lymphocytes and granulocytes using the QIAamp 
DNA Mini Kit (Qiagen). gDNA was also isolated from serial cryosections from frozen muscle 
biopsies using the same QIAamp DNA Mini Kit (Qiagen), and analyzed in the same manner as 
for hematopoietic chimerism. 
Specifically, chimerism was determined by fluorescent variable number of tandem 
repeats (VNTR)-PCR using ABI Prism 310 Genetic Analyzer and Gene Scan 3.1 software 
(Applied Biosystems, Foster City, CA). Primers specific for canine microsatellite 
polymorphisms were used that distinguish donor from recipient [42,43]. 
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Muscle cell isolation, culture and injection. For each experiment, the wild-type donor provided 
two skeletal muscle biopsies, normally harvested from the biceps femoris muscle. The first 
skeletal muscle biopsy was digested with 400 U/ml collagenase type I (Sigma-Aldrich) in 
Hank’s Balanced Salt Solution (HBSS; Invitrogen) or Dulbecco’s Modified Eagle Medium 
(DMEM; Invitrogen) supplemented with 5 mM CaCl2. Mononuclear cells released from the 
muscle were plated on culture dishes and maintained in growth medium (DMEM, 20% FBS, 2.5 
ng/ml bFGF, penicillin and streptomycin, L-glutamine). A preplating technique similar to the 
one described in Qu-Petersen et al (Figure 1b) was employed to separate cell populations based 
on differential adherence. Cells were cultured for 14 days, and maintained at, or below, 70% 
confluence. 
A second skeletal muscle biopsy was removed from the donor on the same day as cells 
were to be injected into the recipient. Again, mononuclear cells were isolated using collagenase 
type I; however, cells were washed twice in PBS, resuspended in 250 μl of PBS, and prepared 
for direct injection (fresh cells). A small aliquot was counted and assayed for viability using 
trypan blue exclusion.  
Adherent cells from the 6th pre-plate (PP6) of the cultured cells described above were 
harvested using a non-enzymatic cell dissociation buffer, washed twice in PBS, the pellet 
resuspended in 250 μl of PBS, and prepared for injection. A small aliquot was counted and 
assayed for viability using trypan blue exclusion.  
A 6-cm incision was made in the skin overlaying the muscle of the immune tolerant xmd 
recipient dog to be injected, and the fascia was gently opened to reveal the body of the muscle. 
Non-dissolvable sutures were placed directly in the muscle, and 5 injections of approximately 50 
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μl each were administered into the muscle surrounding suture, covering approximately 1 cm3. 
The skin was sutured and monitored daily during healing. 
For biopsies of injected sites, another incision was made in the skin, and the muscle 
surrounding each non-dissolvable suture was removed. The muscle biopsies were immediately 
frozen in OCT using liquid nitrogen-cooled isopentane, and stored at -80°C.  
 
Immunostaining. Cryosections were cut (8-10 μm) from frozen muscle biopsies using a Leica 
CM1850 cryostat, and adhered to Superfrost slides (Fisher Scientific). Prior to staining, sections 
were fixed in acetone at -20°C for 10 minutes, allowed to dry, and washed in PBS. Sections were 
blocked in blocking buffer (2% goat serum, 1% BSA, 0.1% cold fish skin gelatin, 0.05% sodium 
azide, 0.01M PBS), and incubated in primary antibody diluted in primary antibody dilution 
buffer (1% BSA, 0.1% cold fish skin gelatin, 0.05% sodium azide, 0.01M PBS). Primary 
antibodies against dystrophin included Dy8/6C5 and Dy4/6D3 (Vector Laboratories). 
Monoclonal antibodies MANDYS102 (7D2), MANDYS107 (4H8), and MANEX1A (4C7), 
specific for dystrophin, were developed by Glenn Morris and obtained from the Developmental 
Studies Hybridoma Bank developed under the auspices of the NICHD and maintained by The 
University of Iowa, Department of Biological Sciences, Iowa City, IA. Other primary antibodies 
used were anti-CD45 (FHCRC Biologics) and anti-CD14 (DAKO). FITC-conjugated anti-mouse 
secondary antibody (Jackson Immunoresearch) was diluted in 1X PBS. Sections were mounted 
using Vectashield containing DAPI. 
 Cultured cells were fixed in 4% paraformaldehyde, and permeabilized with 0.3% Triton 
X-100. Cells were blocked in 10% goat serum, and incubated with primary antibody diluted in 
primary antibody dilution buffer. Primary antibodies specific for Pax7 (Atsushi Kawakami), 
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myogenin (F5D – Woodring E. Wright), and MyHC (MF20 – Donald A. Fischman), were 
obtained from the Developmental Studies Hybridoma Bank. Monoclonal antibody D33 specific 
for desmin was purchased from DAKO. FITC-conjugated anti-mouse secondary antibody 
(Jackson Immunoresearch) was diluted in 1X PBS. Sections were mounted using Vectashield 
containing DAPI. 
 
RNA isolation and real-time RT-PCR. RNA was isolated from groups of serial cryosections cut 
from skeletal muscle biopsies. The cryosections were immediately cut, placed in microcentrifuge 
tubes kept on dry ice, and stored at -80°C until processing. Cryosections were incubated in 
RNALater on ice for 1 minute prior to RNA isolation. RNA was isolated using the RNeasy Mini 
kit (Qiagen), following the tissue isolation protocol. 
Isolated RNA was quantitated using RiboGreen (Invitrogen) and a fluorometer, and 100 
μg was reverse transcribed into cDNA using random hexamers and the High Capacity cDNA 
Reverse Transcription kit (Applied Biosystems), or gene-specific primers and SuperScriptIII 
(Invitrogen). The cDNA was amplified using the BioRad iQ5 system, with primers and TaqMan 
probes specific for dystrophin or β-actin as previously described [27]. Ct values were converted 
to relative expression levels using the ΔΔCt method. 
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Table 1. Chimeric xmd recipients used for muscle cell transplantation.  









G289 11/24/2002 05/15/2003 920 100 100 07/21/2005 
G604 03/18/2005 10/18/2005 200 80 96 09/11/2006 
Abbreviations: HCT, hematopoietic cell transplant; TBI, total body irradiation; MSC, myogenic 
stem cell. 
aThe values for donor chimerism represent the last measurement prior to muscle cell injection. 
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Table 2. Quantitation of wild-type dystrophin transcript in xmd recipient muscle injected 
with fresh cells.a  
Sample Relative Level of Dystrophin 
Expression 
P-value 
G289 – pre-injection 0.00035 ± 0.00009 — 
 – 10 weeks 6.48 ± 0.34 0.00069 
G604 – pre-injection 0.0019 ± 0.0001 — 
 – 4 weeks 1.29 ± 0.25 0.0031 
 – 24 weeks 1.32 ± 0.46 0.010 
WT 100 — 
aRNA isolated from muscle biopsy cryosections was analyzed by quantitative RT-PCR. Values 
represent the average level of wild-type dystrophin transcript present in muscle, relative to 
normal donor, and normalized to β-actin expression (± standard deviation). The level of 
dystrophin expression in the injected samples was compared to the pre-injection sample using 
the Student’s t-test to obtain the P-value. 
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Table 3. Genomic DNA (gDNA) was isolated from groups of serial cryosections from 
skeletal muscle biopsies and analyzed using VNTR-PCR.  
Sample % Average Donor 
gDNAa 
% Highest Value 
Donor gDNA 
P-value 
G289 – pre-injection 13.9 16 — 
 –10 weeks 20.2 23.1 0.0017 
G604 – pre-injection 5.0 5.1 — 
 – 24 weeks 9.3 12.3 0.007 
aThe average donor DNA represents a minimum of 4 groups of cryosections. The percent donor 
gDNA in recipient muscle was compared pre- and post-cell injection using the Student’s t-test, 
and calculated P-values are shown. 
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Table 4. Quantitation of wild-type dystrophin transcript in xmd recipient muscle injected 
with cultured cells.a  
Sample Relative Level of Dystrophin 
Expression 
P-value 
G289 – pre-injection 0.00035 ± 0.00009 — 
 – 10 weeks 1.45 ± 0.15 0.0026 
G604 – pre-injection 0.0019 ± 0.0001 — 
 – 4 weeks 0.05 ± 0.02 0.009 
 – 24 weeks 0.02 ± 0.009 0.16 
WT 100 — 
aRNA isolated from muscle biopsy cryosections was analyzed by quantitative RT-PCR. Values 
represent the average level of wild-type dystrophin transcript present in muscle, relative to 
normal donor, and normalized to β-actin expression (± standard deviation). The level of 
dystrophin expression in the injected samples was compared to the pre-injection sample using 
the Student’s t-test to obtain the P-value. 
 
Molecular Therapy   Manus \ Parker \ Parker_Hct-DMD.doc  4/23/2008 1:51 PM  28 
FIGURE LEGENDS 
 
Figure 1.  (a) Myoblast transplantation in an immune tolerant xmd canine. Wild-type donor 
and xmd recipient dogs were matched by intrafamilial histocompatibility typing. Total body 
irradiation (TBI; 200 or 920 cGy) of the recipient was followed by intravenous infusion of donor 
bone marrow (BM), and peripheral blood mononuclear cells harvested after G-CSF mobilization 
of hematopoietic stem cells from the bone marrow (G-PBMC). The recipient was ready for 
donor myoblast transplantation once stable hematopoietic chimerism was reached. For each 
experiment, the wild-type donor provided two skeletal muscle biopsies, normally harvested from 
the biceps femoris muscle. The first skeletal muscle biopsy was used to isolate mononuclear cells 
for culture prior to injection. The second skeletal muscle biopsy was used to isolate cells were to 
be directly injected into the recipient.  
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(b) Cultured cells were separated into distinct cell populations based on differential 
adherence. Donor muscle-derived cells were plated on culture dishes. After 1 hour, non-
adherent cells were transferred to a new plate, and the adherent cells of the original plate were 
refed with fresh medium. This was repeated at the time intervals indicated until 6 distinct 
populations were obtained – PP1 through PP6. Cells were cultured for 14 days, and maintained 
at, or below, 70% confluence. 
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Figure 2.  (a) Dystrophin expression is restored in full chimeric xmd canine. Myeloablative 
bone marrow transplantation in an xmd recipient (G289) was followed by intramuscular injection 
of muscle-derived cells from the marrow donor. Cryosections from donor muscle, recipient 
muscle pre-injection, and recipient muscle 5-, and 10-weeks after injection of 1x106 freshly 
isolated cells, were stained using an antibody specific for dystrophin (green). DAPI was used to 
visualize nuclei (blue).  
(b) Dystrophin expression is restored in mixed chimeric xmd canine. Non-myeloablative 
bone marrow transplantation in an xmd recipient (G604) was followed by intramuscular injection 
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of muscle-derived cells from the marrow donor. Cryosections from donor muscle, recipient 
muscle pre-injection, and recipient muscle 4-, 8-, and 12-weeks after injection of 4.5x106 freshly 
isolated cells, were stained using an antibody specific for dystrophin (green). DAPI was used to 
visualize nuclei (blue).  
(c) and (d) Lack of immune cell infiltration in xmd recipient muscle injected with donor muscle-
derived cells. Cryosections from donor muscle, recipient muscle pre-injection, and recipient 
muscle 10-weeks after injection of fresh or cultured cells were stained with antibodies specific to 
CD45 (hematopoietic cells; green; c) or CD14 (macrophages; green, d). DAPI (blue) was used to 
visualize nuclei. 
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Figure 3.  (a) Muscle structure is restored in xmd recipient muscle injected with donor 
muscle-derived cells. Cryosections from donor muscle, recipient muscle pre-injection, and 
recipient muscle 10 weeks after injection of freshly isolated cells were stained with hematoxylin 
and eosin. 
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(b) The number of centrally located nuclei is reduced in xmd recipient muscle injected with 
donor muscle-derived cells. The number of centrally located nuclei was counted in 4 randomly 
selected fields of view from serial stained sections in A. Bars represent the average percentage of 
centrally located nuclei in a field of view. Error bars represent standard deviation. The 
percentage of centrally located nuclei after injection was compared to the percentage pre-
injection using the Student’s t-test (*p<0.01). 
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Figure 4. (a) Injection of cultured cells into full chimeric xmd canine. Myeloablative bone 
marrow transplantation in an xmd recipient (G289) was followed by intramuscular injection of 
muscle-derived cells from the marrow donor. Cryosections from donor muscle, recipient muscle 
pre-injection, and recipient muscle 10 weeks after injection of 5x105 cultured cells, were stained 
using an antibody specific for dystrophin (green). DAPI was used to visualize nuclei (blue). 
(b) Injection of cultured cells into mixed chimeric xmd canine. Non-myeloablative bone 
marrow transplantation in an xmd recipient (G604) was followed by intramuscular injection of 
muscle-derived cells from the marrow donor. Cryosections from donor muscle, recipient muscle 
pre-injection, and recipient muscle 24 weeks after injection of 3.0x106 cultured cells, were 
stained using an antibody specific for dystrophin (green). DAPI was used to visualize nuclei 
(blue). 
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Supplemental Figure 1.  (a) Proliferating donor muscle-derived cells are myogenic. 
Adherent PP2 and PP6 cells were fixed in proliferation conditions and immunofluorescence was 
used to detect expression of Pax7 and desmin. Cells were co-stained with DAPI to visualize 
nuclei.  
(b) Cultured donor muscle-derived cells differentiate in vitro. Adherent PP2 and PP6 cells 
were allowed to reach confluence and differentiate for 3 days prior to fixation. 
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Immunofluorescence was used to detect expression of myogenin, myosin heavy chain (MyHC), 
and Pax7 as indicated. Cells were co-stained with DAPI to visualize nuclei.  
